Novo Nordisk Plans Price Cuts for Wegovy and Ozempic Starting 2027

Novo Nordisk will reduce the list price of Wegovy and Ozempic to $675 per month beginning in January 2027, the Danish pharmaceutical company announced, according to CBS Health reporting.

The new pricing represents a reduction from current list prices, CBS Health reported. Wegovy currently carries a list price of approximately $835 per month, while Ozempic lists at around $850 monthly before insurance coverage or manufacturer discounts.

The price reduction comes as Novo Nordisk faces mounting pressure from lawmakers, insurance companies, and patients over the cost of GLP-1 medications. The company has been criticized for charging significantly higher prices in the United States compared to other countries.

Industry analysts note that several factors likely influenced the pricing decision, including looming generic competition as patents begin expiring in the late 2020s. Additionally, ongoing congressional investigations and Medicare price negotiation provisions under the Inflation Reduction Act have increased regulatory scrutiny of drug pricing practices.

The announcement follows a year of supply shortages that have limited patient access to both medications. Novo Nordisk has invested billions in manufacturing expansion to meet demand, with new production facilities coming online through 2026.

Insurance and Access Implications

The price reduction may influence insurance coverage decisions, according to industry observers. Some health plans have restricted access to GLP-1 medications due to cost concerns, requiring prior authorization or covering only specific conditions like diabetes rather than weight loss.

Analysts suggest the move could signal potential industry-wide pricing pressure. Eli Lilly's competing drugs Mounjaro and Zepbound face similar cost criticism, and the company may need to evaluate its own pricing strategy to remain competitive.

The 2027 implementation date gives Novo Nordisk time to adjust revenue projections while aligning with the company's patent timeline. Industry experts expect the price reduction could be offset by increased patient volume as cost barriers decrease.

For patients currently taking these medications, the 2027 timeline means continued reliance on existing cost management strategies for the next two years. Novo Nordisk's current patient assistance program can reduce out-of-pocket costs to as low as $25 per month for eligible patients with commercial insurance, though many patients without adequate coverage still face substantial monthly expenses that can exceed $800.